Best Education For Design

Rimply dummy text of the printing and typesetting industry
lorem Ipsum has been the industry's standard

START A COURSE

READ MORE

Best Education For Design

Rimply dummy text of the printing and typesetting industry
lorem Ipsum has been the industry's standard

START A COURSE

READ MORE

Welcome To IRDiRC

Our vision: Enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention

Goal 1

All patients coming to medical attention with a suspected rare disease will be diagnosed within one year if their disorder is known in the medical literature; all currently undiagnosable individuals will enter a globally coordinated diagnostic and research pipeline

Goal 2

1000 new therapies for rare diseases will be approved, the majority of which will focus on diseases without approved options

Goal 3

Methodologies will be developed to assess the impact of diagnoses and therapies on rare disease patients

Watch Our Presentation Video

Latest News

Fondazione Telethon and Orchard Therapeutics complete transfer of marketing authorization of Strimvelis for ADA-SCID in Europe

September 20, 2023

Following a positive opinion from the European Medicines Agency (EMA), the transfer of…

Defining rare conditions in the era of personalized medicine

September 11, 2023

Don’t miss out the new IRDiRC publication developed by Therapies Scientific Committee (TSC)…

New Publication: Making Rare Disease Research Attractive to Companies by IRDiRC Chrysalis Task Force

September 7, 2023

Accessible at https://doi.org/10.1177/26330040231188979, the Chrysalis Task Force identified key financial and non-financial factors…